Fri-14-10-2022, 16:30 PM
(Fri-14-10-2022, 15:11 PM)Fred Wrote: Update: The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional market authorization for Boehringer Ingelheim’s spesolimab as first in class treatment option for generalized pustular psoriasis (GPP) flares in adults.
That is sounding good. As GPP is one of the less nice forms of psoriasis, so great if there is something that can fight it.